ArticleCancer science2020

Abemaciclib, a CDK4/6 inhibitor, exerts preclinical activity against aggressive germinal center-derived B-cell lymphomas.

Yuka Tanaka et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.